This phase II trial studies how well talazoparib works in treating patients with homologous recombination repair deficiency (HRRD) positive stage IV squamous cell lung cancer that has come back after previous treatment. Talazoparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Completed
Phase 2
| Drug | Synonyms | Arms |
|---|---|---|
| Talazoparib | BMN 673, BMN-673 | Treatment (talazoparib) |
PRIMARY OBJECTIVES:
I. To evaluate the overall response rate (ORR) (confirmed and unconfirmed, complete and
partial) with talazoparib (BMN 673) in HRRD Medivation (MDVN)-positive patients.
SECONDARY OBJECTIVES:
I. To evaluate investigator assessed progression-free survival (IA-PFS) and overall survival
(OS) associated with therapy in HRRD MDVN-positive patients.
II. To evaluate ORR, IA-PFS, and OS in HRRD Foundation Medicine, Inc. (FMI)-positive
patients.
III. To evaluate ORR in HRRD MDVN-negative/HRRD FMI-positive patients. IV. To evaluate the
frequency and severity of toxicities associated with talazoparib (BMN 673) in HRRD
FMI-positive patients.
TERTIARY OBJECTIVES:
I. To assess if the homologous recombination deficiency (HRD) score is associated with
clinical outcomes (response, PFS, OS) in HRRD FMI-positive patients treated with talazoparib
(BMN 673).
II. To assess if the level of PARP protein expression determined by immunohistochemistry is
associated with clinical outcomes (response, PFS, OS) in HRRD FMI-positive patients treated
with talazoparib (BMN 673).
III. To characterize pharmacokinetic properties of talazoparib (BMN 673).
OUTLINE:
Patients receive talazoparib orally (PO) once daily (QD) on days 1-21. Courses repeat every
21 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months for 1 year,
every 6 months for 2 years, and at the end of year 3.
| Name | Type | Description | Interventions |
|---|---|---|---|
| Treatment (talazoparib) | Experimental | Patients receive talazoparib PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. |
|
Inclusion Criteria:
- Patients must meet all SCREENING/PRE-SCREENING and SUB-STUDY REGISTRATION COMMON
ELIGIBILITY CRITERIA as specified in S1400: Phase II/III Biomarker-Driven Master
Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
- Patients must be assigned to S1400G; S1400G biomarker eligibility defined as
homologous recombination repair deficiency (HRRD) positive is as follows
- Biomarker-positive group
- HRRD by FMI
- Homologous recombination repair deficiency by Foundation Medicine Inc.,
criteria
- Alteration type
- Truncating mutation, frameshift deletions, indels missense and nonsense
mutations predicted to have functional consequence in any of the specified
genes
- Eligible alteration
- Mutation in any one of the following critical HRR pathway genes: ATM, ATR,
BARD1, BRCA1, BRCA2, BRIP1, CHEK1, CHEK2, FANCA, FANCC, FANCD2, FANCF,
FANCM, NBN (NBS1), PALB2, RAD51, RAD51B (RAD51L1), RAD54L, RPA1
- Patients must not have had prior exposure to any agent with a PARP inhibitor (e.g.,
veliparib, olaparib, rucaparib, niraparib, talazoparib [BMN 673]) as its primary
pharmacology
- Patients must have achieved stable disease, a partial response, or a complete response
at their first disease assessment after initiating first-line platinum-based
chemotherapy; patients determined to have progressed (in the opinion of the treating
physician) at their first disease assessment are not eligible
- Patients may not have any impairment of gastrointestinal function or gastrointestinal
disease that may significantly alter the absorption of talazoparib (BMN 673) (e.g.,
ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome,
small bowel resection, or active peptic ulcer disease); patients must not have active
small or large intestine inflammation such as Crohn's disease or ulcerative colitis
(within 12 months of sub-study registration)
- Patients must be able to take oral medications; patients must be able to swallow
capsules whole without crushing or altering them in any way
- Patients must not be taking, nor plan to take while on protocol treatment strong
P-glycoprotein (P-gp) inhibitors, P-gp inducers, or breast cancer resistance protein
(BCRP) inhibitors; the language ?P-gp or BCRP inhibitors or inducers? is reworded to
?strong P-gp inhibitors, P-gp inducers, or BCRP inhibitors? for consistency with the
investigator brochure
- Patients must agree to have blood specimens submitted for pharmacokinetic analysis
| Maximum Eligible Age: | N/A |
| Minimum Eligible Age: | N/A |
| Eligible Gender: | All |
| Healthy Volunteers: | No |
| Measure: | Overall Response Rate Assessed by Response Evaluation Criteria in Solid Tumors 1.1 in HRRD-positive (MDVN) Participants |
| Time Frame: | Up to 3 years post sub-study registration |
| Safety Issue: | |
| Description: | The percentage of participants with confirmed and unconfirmed, partial response and complete response to treatment with talazoparib per Response Evaluation Criteria in Solid Tumors Criteria (RECIST 1.1). Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI or CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR Analysis was performed using a more restricted definition of homologous recombination repair deficiency (HRRD)-positivity (Medivation [MDVN] criteria; defined by alterations in ATM/ATR/BRCA1/BRCA2/PALB2 genes). With 40 HRRD subset positive patients, overall response rate can be estimated within 13% with 95% confidence. |
| Measure: | Investigator-assessed Progression-free Survival (IA-PFS) in HRRD-positive (MDVN) Participants |
| Time Frame: | Up to 3 years post sub-study registration |
| Safety Issue: | |
| Description: | From date of sub-study registration to date of first documentation of progression assessed by local review or symptomatic deterioration or death due to any cause. Participants last known to be alive without report of progression were censored at date of last disease assessment. Analysis was performed using a more restricted definition of homologous recombination repair deficiency (HRRD)-positivity (Medivation [MDVN] criteria; defined by alterations in ATM/ATR/BRCA1/BRCA2/PALB2 genes). |
| Measure: | Overall Survival (OS) in HRRD-positive (MDVN) Participants |
| Time Frame: | Up to 3 years post sub-study registration |
| Safety Issue: | |
| Description: | From date of sub-study registration to date of death due to any cause. Participants last known to be alive were censored at date of last contact. Analysis was performed using a more restricted definition of homologous recombination repair deficiency (HRRD)-positivity (Medivation [MDVN] criteria; defined by alterations in ATM/ATR/BRCA1/BRCA2/PALB2 genes). |
| Measure: | Overall Response Rate Assessed by Response Evaluation Criteria in Solid Tumors 1.1 in HRRD-positive (FMI) Participants |
| Time Frame: | 3 years post sub-study registration |
| Safety Issue: | |
| Description: | The percentage of participants with confirmed and unconfirmed, partial response and complete response to treatment with talazoparib per Response Evaluation Criteria in Solid Tumors Criteria (RECIST 1.1). Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI or CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR Analysis was performed using a broader definition of homologous recombination repair deficiency (HRRD)-positivity (Foundation Medicine Inc. [FMI] criteria; defined by alterations in ATM/ATR/BARD1/BRCA1/BRCA2/BRIP1/CHEK1/CHEK2/FANCA/FANCC/FANCD2/FANCF/FANCM/NBN(NBS1)/PALB2/RAD51/RAD51B(RAD51L1)/RAD54L/RPA1 genes). |
| Measure: | Investigator-assessed Progression Free Survival (IA-PFS) FEP in HRRD-positive (FMI) Participants |
| Time Frame: | 3 years post sub-study registration |
| Safety Issue: | |
| Description: | From date of sub-study registration to date of first documentation of progression assessed by local review or symptomatic deterioration or death due to any cause. Participants last known to be alive without report of progression were censored at date of last disease assessment. Analysis was performed using a broader definition of homologous recombination repair deficiency (HRRD)-positivity (Foundation Medicine Inc. [FMI] criteria; defined by alterations in ATM/ATR/BARD1/BRCA1/BRCA2/BRIP1/CHEK1/CHEK2/FANCA/FANCC/FANCD2/FANCF/FANCM/NBN(NBS1)/PALB2/RAD51/RAD51B(RAD51L1)/RAD54L/RPA1 genes). |
| Measure: | Overall Survival (OS) in HRRD-positive (FMI) Participants |
| Time Frame: | 3 years post sub-study registration |
| Safety Issue: | |
| Description: | From date of sub-study registration to date of death due to any cause. Participants last known to be alive were censored at date of last contact. Analysis was performed using a broad definition of homologous recombination repair deficiency (HRRD)-positivity (Foundation Medicine Inc. [FMI] criteria; defined by alterations in ATM/ATR/BARD1/BRCA1/BRCA2/BRIP1/CHEK1/CHEK2/FANCA/FANCC/FANCD2/FANCF/FANCM/NBN(NBS1)/PALB2/RAD51/RAD51B(RAD51L1)/RAD54L/RPA1 genes). |
| Measure: | Duration of Response in HRRD-positive (FMI) Participants |
| Time Frame: | Up to 3 years |
| Safety Issue: | |
| Description: | From date of documentation of response (complete or partial) to date of first documentation of progression assessed by local review or symptomatic deterioration or death due to any cause among participants who achieve a complete or partial response. |
| Measure: | Overall Response Rate Assessed by Response Evaluation Criteria in Solid Tumors 1.1 in HRRD-negative Per MDVN But HRRD-positive Per FMI Participants |
| Time Frame: | 3 years post sub-study registration |
| Safety Issue: | |
| Description: | The percentage of participants with confirmed and unconfirmed, partial response and complete response to treatment with talazoparib per Response Evaluation Criteria in Solid Tumors Criteria (RECIST 1.1). Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI or CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR Analysis was performed on participants that meet a broader definition of homologous recombination repair deficiency (HRRD)-positivity (Foundation Medicine Inc.) but not the stricter definition set by MDVN. [FMI] criteria; defined by alterations in ATM/ATR/BARD1/BRCA1/BRCA2/BRIP1/CHEK1/CHEK2/FANCA/FANCC/FANCD2/FANCF/FANCM/NBN(NBS1)/PALB2/RAD51/RAD51B(RAD51L1)/RAD54L/RPA1 genes). |
| Measure: | Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs |
| Time Frame: | Duration of treatment and follow up until death or 3 years post registration |
| Safety Issue: | |
| Description: | Adverse Events (AEs) are reported by CTCAE Version 4.0. Only adverse events that are possibly, probably or definitely related to study drug are reported. |
| Phase: | Phase 2 |
| Primary Purpose: | Interventional |
| Overall Status: | Completed |
| Lead Sponsor: | Southwest Oncology Group |
June 23, 2021
